Sganga, Gabriele
Wang, Minggui
Capparella, M. Rita
Tawadrous, Margaret
Yan, Jean L.
Aram, Jalal A.
Montravers, Philippe
Funding for this research was provided by:
Pfizer
Article History
Received: 27 February 2019
Accepted: 14 June 2019
First Online: 6 July 2019
Compliance with ethical standards
:
: G. Sganga is an employee of Catholic University of the Sacred Heart, Fondazione Agostino Gemelli University Hospital, Rome, Italy. M. Wang is an employee of Huashan Hospital, Fudan University, Shanghai, China. M.R. Capparella is an employee and shareholder of Pfizer PIO, Paris, France. M. Tawadrous, J.L. Yan and J.A. Aram are employees and shareholders of Pfizer Inc, USA. P. Montravers has no conflict of interest to declare.
: All primary studies were conducted in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines established by the International Conference on Harmonization. The final protocols, amendments and informed consent documentation were reviewed and approved by the Institutional Review Boards and the Independent Ethics Committees of the investigational centres.
: All patients provided written informed consent.